Are peptides legal in the UK?

There is no blanket UK ban on peptides. The large majority of research peptides are lawful to purchase, possess and supply as research reference materials that are not for human or veterinary use. A minority — principally growth-hormone analogues and licensed medicines such as the GLP-1 class — sit inside specific control or prescription regimes that change what may lawfully be done with them.

Two questions decide the status of any individual compound: (1) is the molecule itself a controlled drug, and (2) is it being presented or supplied for human use? NMChem supplies every compound strictly as a research material, not for human consumption.

Under the Human Medicines Regulations 2012 a substance becomes a regulated "medicinal product" either by presentation (it is marketed as treating or preventing disease) or by function (it is supplied for administration to people). A compound sold purely as a laboratory reference material — with no medical claims, no dosing guidance and an explicit research-use-only condition — falls outside that medicines regime. This is precisely why research-use framing is not a marketing slogan but the legal basis on which these materials are supplied.

Compounds in this group include peptides such as BPC-157, TB-500, Ipamorelin, GHK-Cu and Selank. None of these is a controlled drug in the UK. Their lawful supply depends on their being sold for research rather than for human administration.

Human growth hormone (somatropin) and insulin-like growth factor 1 are Class C controlled drugs under the Misuse of Drugs Act 1971 (Schedule 4, Part II of the Misuse of Drugs Regulations 2001). Possession of a Schedule 4 Part II substance is not itself an offence without intent to supply, but production and supply are offences. This places HGH and IGF-1 in a different category from ordinary research peptides, and NMChem's per-compound reference pages flag that status individually.

The incretin class — semaglutide, tirzepatide and the investigational triple agonist retatrutide — corresponds to licensed or trial-stage medicines. Where a licensed product exists, the molecule is a Prescription-Only Medicine under the Human Medicines Regulations 2012. It is lawful to possess, but supplying it for human use requires a prescription. Supplied as a research reference material rather than for administration, it sits outside that supply restriction — which is the only basis on which it is offered here.

Melanotan II is not a controlled drug, but the MHRA has repeatedly acted against its sale for human use. It is a useful illustration of the "by presentation" rule: a compound that is otherwise unrestricted can still breach the medicines regulations if it is marketed or sold for people to use. The dividing line is intended use, not the molecule alone.

Every compound on this site is supplied as a research reference material, not for human or veterinary use, food, cosmetic or therapeutic application. Buyers confirm the research-use condition at checkout. Compound-specific regulatory notes appear on each research reference page, and our compliance page sets out the supply terms in full.